利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

210 条记录 (耗时 0.028 秒)

    ORGANIC ELECTROLUMINESCENT ELEMENT
    2.
    发明授权
    ORGANIC ELECTROLUMINESCENT ELEMENT 审中-公开

    公开(公告)号：EP2492988B1

    公开(公告)日：2018-12-26

    申请号：EP10825088.7

    申请日：2010-10-21

    申请人： Sumitomo Chemical Company, Limited

    发明人： SOGA, Masayuki ,  ISHII, Yusuke

    IPC分类号： H01L51/50 ,  C07D213/22 ,  C07D251/16 ,  C07D265/38 ,  C08K5/3432 ,  C08L65/00

    CPC分类号： C07D213/22 ,  C07D251/16 ,  C07D265/38 ,  C08G61/12 ,  C08G61/122 ,  C08G2261/135 ,  C08G2261/141 ,  C08G2261/3162 ,  C08G2261/3221 ,  C08K5/3432 ,  H01L51/0035 ,  H01L51/0039 ,  H01L51/0043 ,  H01L51/0085 ,  H01L51/5004 ,  H01L51/5016 ,  H01L51/5048 ,  C08L65/00

    摘要： An organic electroluminescent device comprising an anode, a cathode, a light emitting layer that is disposed between the anode and the cathode and contains a first light emitting layer material containing a phosphorescent compound and a second light emitting layer material containing a charge transporting polymer compound (that is, a light emitting layer containing a first light emitting layer material and a second light emitting layer material), and a hole transporting layer that is disposed between the anode and the light emitting layer so as to be adjacent to the light emitting layer and is composed of a hole transporting polymer compound, wherein the lowest excitation triplet energy T1 e (eV) of the first light emitting layer material, the lowest excitation triplet energy T1 h (eV) of the second light emitting layer material and the lowest excitation triplet energy T1 t (eV) of the hole transporting polymer compound satisfy the following formulae (A) and (B): An organic electroluminescent device comprising an anode and a cathode, and a hole transporting layer and a light emitting layer disposed between the anode and the cathode, wherein the hole transporting layer contains 1) a mixture of 2,2'-bipyridine and/or 2,2'-bipyridine derivative and a non-2,2'-bipyridinediyl group-containing hole transporting polymer compound, 2) a 2,2'-bipyridinediyl group-containing polymer compound having a constitutional unit composed of an unsubstituted or substituted 2,2'-bipyridinediyl group, and at least one constitutional unit selected from the group consisting of constitutional units composed of a divalent aromatic amine residue and constitutional units composed of an unsubstituted or substituted arylene group, or a combination thereof.

    Compositions and methods for bone formation and remodeling
    10.
    发明公开
    Compositions and methods for bone formation and remodeling 审中-公开
    成分和骨形成，并形成行业方法

    公开(公告)号：EP2910550A3

    公开(公告)日：2015-10-28

    申请号：EP15150525.2

    申请日：2007-08-29

    申请人： ENZO THERAPEUTICS, INC.

    发明人： Wu, Dianqing (dan) ,  Liu, Dakai ,  Donegan, James, J.

    IPC分类号： C07D265/38 ,  A01N43/00 ,  A61K31/33

    CPC分类号： A61K31/538 ,  C07D265/38 ,  C09B19/005

    摘要： The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.